Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis.
Insulin resistance and obesity is a common health problem in the industrialized world. As a result of the availability of high-calorie food and a reduction in energy expenditure, maladaptive metabolic processes may interfere with the action of insulin and increase susceptibility for the development of atherosclerotic cardiovascular diseases. With the advent of peroxisome proliferator-activated receptors (PPARs), the mechanisms of this maladaptation and its relationship to insulin resistance syndrome components have become less obscure, promising new therapeutic approaches for this common problem. In this review we first focus on the molecular structure and cellular mechanisms of action of these receptors and then discuss how PPAR-gamma, a PPAR isoform, provides a link between adiposity, insulin resistance, and atherosclerosis.
Kepez
Alper
A
Cardiology Department, Hacettepe University Faculty of Medicine, Ankara, Turkey. alperkepez@yahoo.com
Oto
Ali
A
Dagdelen
Selcuk
S
D050154:Adiposity / Q000187:drug effects*; D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance; D008024:Ligands; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D047495:PPAR gamma / Q000378:metabolism* / Q000502:physiology; D045162:Thiazolidinediones / Q000493:pharmacokinetics / Q000627:therapeutic use
D008024:Ligands; D047495:PPAR gamma; D045162:Thiazolidinediones